Business Context and Reporting Period
Equillium, Inc. filed a Form 8-K on November 10, 2021, under Item 2.02 to announce financial results for the third quarter ended September 30, 2021, and provide a business update. Equillium is a Delaware corporation whose common stock trades on the Nasdaq Global Select Market under the symbol EQ.
Financial Metrics
The provided filing text does not include the reported revenue, net loss, cash flow, margins, debt, cash balance, liquidity, or other financial metrics. Those details were contained in the press release furnished as Exhibit 99.1, which is not included in the provided source text.
Material Changes Versus Prior Period
The filing states that third-quarter 2021 results and a business update were announced, but it does not provide the underlying figures or a clear comparison with the prior comparable period.
Guidance, Outlook, Risks, and Unusual Items
The filing text does not provide specific guidance, outlook, risk updates, contingencies, or unusual items. It references a business update in Exhibit 99.1.
The Item 2.02 information and Exhibit 99.1 were furnished rather than filed for purposes of Section 18 of the Exchange Act and are not incorporated by reference into other SEC filings, regardless of general incorporation language.
Investor Verification Items
- Review Exhibit 99.1 for third-quarter 2021 revenue, net loss, cash flow, cash balance, liquidity runway, and research and development expenses.
- Verify management’s business update, clinical-development milestones, financing needs, and any forward-looking guidance.
- Check the complete filing and accompanying press release for changes in debt, contractual obligations, risks, or contingencies.